In 3SBio, meeting the needs of patients is the core of all actions.
The following is a list of products listed by our company, which is only for medical professionals to refer to.
YISAIPU was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 3 kinds of indications were approved by the NMPA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
| Indication | Manufacturing base | Dosage form & Dosage |
|
Moderate to severe rheumatoid arthritis; Moderate to severe plaque psoriasis (PS) in adults aged 18 or above; Active ankylosing spondylitis. |
Shanghai manufacturing base | 12.5 mg/bottle; 25 mg/bottle |